Looking Ahead: Puberty and Adulthood with Laron Syndrome
At a Glance
Laron syndrome may delay and prolong puberty and can affect body fat, fertility, blood sugar, cholesterol, and liver health in adulthood. Mecasermin usually stops when growth plates close, but ongoing endocrine care and routine cancer screening remain important.
As your child grows, the focus of care will naturally shift from promoting height to maintaining long-term metabolic health. Understanding what to expect during puberty and adulthood can help you prepare for these transitions and advocate for your child’s lifelong well-being.
Puberty: A Slower, Later Timeline
In children with Laron syndrome, puberty often follows a different timeline than in their peers. It is common for the onset of puberty to be delayed [1][2].
- Delayed and Prolonged: Research has shown that puberty may start later and take longer to complete [1]. For example, in a review of untreated males, about 35% experienced delayed puberty, and for the vast majority (77%), the process was prolonged [1].
- Sexual Development: While development may be slower, sexual maturation does occur. However, fertility varies among individuals [2]. Reproductive health can be influenced by genotype, metabolic factors like obesity, and specific anatomical developments [3]. If you have concerns about delayed puberty or future fertility, an endocrinologist or reproductive specialist can provide tailored support.
- Physical Findings: In males, features such as a micropenis (a smaller than average penis) are common [1]. Your endocrinologist will monitor these developments and may discuss hormone support if needed.
Metabolic Health in Adulthood
Laron syndrome affects how the body processes energy, leading to a unique metabolic profile in adulthood.
- Body Composition: Most adults with Laron syndrome have a high percentage of body fat, even if their BMI (Body Mass Index) doesn’t seem extremely high [4][5]. This is often called truncal obesity [1].
- Contrasting Health Profiles: Interestingly, different groups of patients show different health outcomes.
- In some groups (such as an Israeli cohort), adults frequently developed metabolic syndrome, including high blood pressure, high cholesterol (dyslipidemia), and type 2 diabetes [4].
- In contrast, a famous cohort in Ecuador showed a lower risk of diabetes and higher insulin sensitivity (the body’s ability to use sugar effectively) despite having high body fat [5][6].
- Cardiovascular Care: Because the risk of high cholesterol and fatty liver disease is real, adult care involves individualized, regular monitoring of heart health and blood sugar levels [4][7].
The Question of “Cancer Protection”
You may hear that people with Laron syndrome are “protected” from cancer. This idea comes from long-term observational studies of the Ecuadorian group, which found significantly lower rates of cancer compared to their relatives [8][6].
- The Theory: Scientists believe that because these individuals have very low levels of IGF-1—a hormone that helps cells grow and divide—this may influence cell replication [8][9].
- The Reality: This finding is not absolute and should be viewed as an observational association, not a proven protection. There have been documented cases of cancer in people with Laron syndrome [10]. It is vital to continue routine cancer screenings according to age, sex, and family history guidelines, as the findings from one cohort may not apply to everyone [10][11].
When Treatment Ends
The specialized treatment with Mecasermin (IGF-1) is specifically designed to promote height.
- Closing Growth Plates: Growth-promoting treatment typically stops when the growth plates (epiphyses) in the long bones close [12]. This closure is triggered by the hormones of puberty [13].
- Bone Age Monitoring: Your doctor will use hand X-rays to determine “bone age.” Once the bones have finished maturing and the plates have fused, no further height can be gained, and the injections are usually discontinued [14][12].
While the injections stop, the need for a “home” for your child’s care—ideally with an adult endocrinologist familiar with rare growth disorders—continues into adulthood [15]. Moving from pediatric to adult care is a significant milestone that ensures your child’s metabolic and reproductive health stays monitored throughout their life.
Common questions in this guide
Is delayed puberty common in children with Laron syndrome?
Can Laron syndrome affect fertility?
What health problems should adults with Laron syndrome be monitored for?
Does Laron syndrome protect against cancer?
When is mecasermin stopped in Laron syndrome?
Does care continue after a child reaches adult height?
Get notified when new evidence is published on Laron syndrome.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.
References
References (15)
- 1
Role of the GH-IGF1 axis on the hypothalamus-pituitary-testicular axis function: lessons from Laron syndrome.
Cannarella R, Crafa A, La Vignera S, et al.
Endocrine connections 2021; (10(9)):1006-1017.
PMID: 34319907 - 2
LESSONS FROM 50 YEARS OF STUDY OF LARON SYNDROME.
Laron Z
Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists 2015; (21(12)):1395-402 doi:10.4158/EP15939.RA.
PMID: 26401581 - 3
Treatment for Infertility in Laron Syndrome: A Case Report.
Alhazidou E, Vlachadis N, Androulaki M, et al.
Cureus 2022; (14(12)):e33090 doi:10.7759/cureus.33090.
PMID: 36721555 - 4
Adult patients with Laron syndrome tend to develop the metabolic syndrome.
Laron Z, Kauli R, Silbergeld A
Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society 2024; (78()):101605 doi:10.1016/j.ghir.2024.101605.
PMID: 39084176 - 5
GH Receptor Deficiency in Ecuadorian Adults Is Associated With Obesity and Enhanced Insulin Sensitivity.
Guevara-Aguirre J, Rosenbloom AL, Balasubramanian P, et al.
The Journal of clinical endocrinology and metabolism 2015; (100(7)):2589-96 doi:10.1210/jc.2015-1678.
PMID: 25985182 - 6
Insights from the clinical phenotype of subjects with Laron syndrome in Ecuador.
Guevara-Aguirre J, Bautista C, Torres C, et al.
Reviews in endocrine & metabolic disorders 2021; (22(1)):59-70 doi:10.1007/s11154-020-09602-4.
PMID: 33047268 - 7
Normal or improved cardiovascular risk factors in IGF-I-deficient adults with growth hormone receptor deficiency.
Guevara-Aguirre J, Mishra A, Canepa M, et al.
Med (New York, N.Y.) 2024; (5(7)):816-825.e4 doi:10.1016/j.medj.2024.03.022.
PMID: 38677286 - 8
Cancer in Ecuadorian subjects with Laron syndrome (ELS).
Guevara-Aguirre J, Peña G, Pazmiño G, et al.
Endocrine-related cancer 2023; (30(6)).
PMID: 36971780 - 9
Laron Syndrome Research Paves the Way for New Insights in Oncological Investigation.
Werner H, Sarfstein R, Nagaraj K, Laron Z
Cells 2020; (9(11)) doi:10.3390/cells9112446.
PMID: 33182502 - 10
Marjolin's Ulcer in Laron Syndrome - an Unexpected Combination: A Case Report.
de la Paz EM
Malaysian orthopaedic journal 2020; (14(1)):78-80 doi:10.5704/MOJ.2003.012.
PMID: 32296486 - 11
Clinical and Molecular Features of Laron Syndrome, A Genetic Disorder Protecting from Cancer.
Janecka A, Kołodziej-Rzepa M, Biesaga B
In vivo (Athens, Greece) 2016; (30(4)):375-81.
PMID: 27381597 - 12
Short and tall stature: a new paradigm emerges.
Baron J, Sävendahl L, De Luca F, et al.
Nature reviews. Endocrinology 2015; (11(12)):735-46 doi:10.1038/nrendo.2015.165.
PMID: 26437621 - 13
Approach to the Peripubertal Patient With Short Stature.
Torres-Santiago L, Mauras N
The Journal of clinical endocrinology and metabolism 2024; (109(7)):e1522-e1533 doi:10.1210/clinem/dgae011.
PMID: 38181434 - 14
Sequential measurements of IGF-I serum concentrations in adolescents with Laron syndrome treated with recombinant human IGF-I (rhIGF-I).
Breil T, Kneppo C, Bettendorf M, et al.
Journal of pediatric endocrinology & metabolism : JPEM 2018; (31(8)):895-902 doi:10.1515/jpem-2018-0139.
PMID: 29995632 - 15
Growth hormone insensitivity: Mexican case report.
Castilla-Cortazar I, De Ita JR, Aguirre GA, et al.
Endocrinology, diabetes & metabolism case reports 2017; (2017()) doi:10.1530/EDM-17-0126.
PMID: 29147569
This page provides general information about puberty and adulthood with Laron syndrome for informational purposes only and does not constitute medical advice. Your child’s endocrinology team should tailor growth, hormone, metabolic, reproductive, and screening decisions to their specific situation.